theheart.org : Acute Coronary Syndromes

Acute Coronary Syndromes

Best Practices in STEMI Management: The Crossroads of Bleeding and Outcomes

Feb 3, 2010 10:49 EST

Dr. Gabriel Steg introduces a discussion between Drs. Anthony Gershlick and Martial Hamon on achieving a balance between favorable outcomes and reducing bleeding in STEMI patients.

Acute Coronary Syndromes

Antiplatelets in PCI: Doses and Choices

Jan 21, 2010 13:36 EST

Recent data on aspirin and clopidogrel dosing in PCI have left many confused. Dr. Ohman navigates through the data with Drs. Gurbel and Storey.

Acute Coronary Syndromes

Antiplatelet Therapy for Atherothrombotic Disease: Taking the Next Steps

1 COMMENT - Jan 4, 2010 14:37 EST

Examine current perspectives in antiplatelet therapy on emerging agents vs current therapy, and review data from recently completed clinical trials.

Acute Coronary Syndromes

Stent Thrombosis: A Case-Based Discussion

Dec 17, 2009 14:59 EST

Dr. Holmvang presents 2 cases of stent thrombosis to Dr. Kristensen outlining risk factors and potential strategies to prevent this catastrophic event.

Acute Coronary Syndromes

Antiplatelet Therapy in ACS: Copenhagen Masterclass Roundtable

Dec 16, 2009 16:10 EST

What are the implications of recent data on the antiplatelet agents in ACS for Europe? Recorded at the 2009 ACS Masterclass in Copenhagen, Denmark, Dr. Clemmensen leads a roundtable discussion with Drs. Collet, Kristensen, and Schühlen.

Acute Coronary Syndromes

Thrombosis: Describing the Clinical Link Between the Coagulation Cascade and Platelet Function

2 COMMENTS - Dec 14, 2009 17:21 EST

Join Drs. Alexander, Becker, and Weitz for a discussion on the coagulation cascade, its link to platelet function, and the risk/benefit and clinical utility of agents that target the coagulation cascade and platelet receptors.

Acute Coronary Syndromes

Translating Evidence From Trials With Antiplatelet Agents Into Clinical Practice

Dec 8, 2009 10:03 EST

Recently reported and new trials of antiplatelet therapy continue to redefine optimal management strategies for patients with atherothrombotic disease and patients with atrial fibrillation. Drs. Harrington, Angiolillo, Bhatt, Connolly, Mehta, and Simon discuss guidelines? recommendations for the use of antiplatelet therapies and the potential impact of emerging data regarding currently used and novel antiplatelet agents.

Acute Coronary Syndromes

Antiplatelet Therapy in ACS: Evidence-Based Medicine in Real-World Practice

1 COMMENT - Dec 7, 2009 12:46 EST

With the approval of a third-generation thienopyridine, new clinical trial data on novel agents, and the dosing of clopidogrel, Dr. Berger asks Dr. Cohen how he has incorporated this information into his practice.

Acute Coronary Syndromes

Antiplatelet Therapy in Patients With ACS - What Is the Role of New Agents?

Dec 4, 2009 13:41 EST

After all these years with aspirin and clopidgrel, we are still learning about when and how much of these antiplatelet agents confer the best benefit risk approach. Now new agents like prasugrel add to the options with other new agents on the horizon. Drs Lopes, Granger, Alexander, and Mattos discuss applying trial data to practice in the United States and Latin America.

Acute Coronary Syndromes

The Genetics of Antiplatelet Responsiveness

3 COMMENTS - Dec 4, 2009 11:21 EST

Carriers of certain CYP genetic variants have lower levels of clopidogrel's active metabolite and experience higher rates of MACE. What role should genotyping play in optimizing antiplatelet therapy? Dr. Simon discusses recent data on these topics with Dr. Mega.

Acute Coronary Syndromes

Triple Therapy/Triple Threat? Dual Antiplatelet Therapy in Patients on Oral Anticoagulation

1 COMMENT - Nov 30, 2009 13:35 EST

Dual antiplatelet therapy carries a risk for bleeding that is heightened in the setting of oral anticoagulation. What is the best way to manage patients who may need triple therapy? Using a real-world clinical scenario, Dr. Ohman walks through the issues with Drs. Holmes and Moliterno.

Acute Coronary Syndromes

Improving Outcomes in STEMI: Management of Adjunctive Antithrombotic Therapy in ACS

Nov 26, 2009 11:27 EST

Our international panel of experts, Drs. Hamm, Verheugt, Dauerman, and Rao, give their insights into which antiplatelet and antithrombotic agents they prefer to use and when.

Acute Coronary Syndromes

Balancing Acts: Evaluating the Net Clinical Benefit of Antiplatelet Therapy in ACS

Nov 11, 2009 13:30 EST

Drs. Gurbel, Ohman, and Berger discuss the major issues of optimal duration of dual antiplatelet therapy, balancing the risk/benefit profile, the relevance of point-of-care (POC) monitoring, and consideration to the potential drug-drug interactions between antiplatelet agents and statins/CCBs/PPIs in treating patients with ACS.

Acute Coronary Syndromes

Focus On: Antiplatelet Therapy at ESC

Oct 30, 2009 10:23 EDT

PLATO, CURRENT-OASIS 7, and further analyses of PPIs and thienopyridines; read Dr Prasad's review of recent data presented at ESC; and watch presentations by Drs Mehran, O'Donoghue, Storey, and Wiviott.

Acute Coronary Syndromes

Tips and Approaches to Reducing Bleeding in PCI

1 COMMENT - Oct 29, 2009 11:37 EDT

Join Drs. Bhatt, Rao, and Stone as they discuss important clinical trial data which will improve management strategies for patients undergoing PCI.

Acute Coronary Syndromes

The Role of Antiplatelet Therapy in the Management of Patients with NSTE ACS

1 COMMENT - Oct 28, 2009 10:46 EDT

In the US, each year over 1.4 million people will be hospitalized for unstable angina (UA) and non-ST-segment-elevation myocardial infarction (NSTEMI). Multiple antiplatelet agents have been developed to interfere with or inhibit the specific pathways of platelet activation and aggregation that lead to the development of UA and NSTEMI. Join Drs Newby, Popma, and Wiviot as they discuss.

Acute Coronary Syndromes

Antiplatelet Therapy in ACS: The Latest Dialogues

Oct 15, 2009 16:09 EDT

PLATO, the ESC late-breaking trial, compared a novel direct-acting reversible P2Y12 antagonist with clopidogrel in ACS patients undergoing PCI. Dr. Keith Fox leads a discussion with the PI, Dr. Lars Wallentin, and Dr. Deepak Bhatt.

Interventional/Surgery

Dual Antiplatelet Therapy: Dueling Options in Real-World Practice

3 COMMENTS - Sep 30, 2009 13:31 EDT

With the recent approval of a third-generation thienopyridine, choice of agent can be added to the list of considerations in the management of ACS patients, as well as the appropriate timing and dosing of thienopyridine. Using some case vignettes, Dr. King leads a discussion with Drs. Bhatt and Steg on their clinical decision-making.

Acute Coronary Syndromes

Best Practices for the Treatment of STEMI: How Can We Decrease Mortality?

2 COMMENTS - Sep 21, 2009 09:56 EDT

Patients presenting with STEMI represent a high-risk population. Thrombotic and bleeding complications contribute to mortality in these patients. Join Drs. Steg, Hamm, Hill, and Mehran as they discuss best practices for the treatment of STEMI patients with a focus on preventing bleeding complications.

Acute Coronary Syndromes

In Brief: Optimal Use of Dual Antiplatelet Therapy...

Sep 15, 2009 15:44 EDT

Antiplatelet therapy is key for the prevention of secondary events in ACS patients. Dr. Ardissino introduces a series of brief presentations by Drs. Angiolillo, Fernánadez-Avilés, Montalescot, and Neumann on the optimal use of antiplatelets in ACS patients undergoing PCI, including those with diabetes and those at high bleeding risk.

Acute Coronary Syndromes

Antiplatelet Therapy in PCI: Addressing Unmet Needs

Aug 28, 2009 11:29 EDT

How will the prasugrel approval and the upcoming PLATO and CURRENT-OASIS 7 trials affect antiplatelet options for ACS patients undergoing PCI? Read a summary of the latest data, with expert input from Drs. Ardissino and Montalescot.

Acute Coronary Syndromes

Managing Bleeding Complications in PCI

Aug 12, 2009 13:40 EDT

A patient suffers a STEMI after exploratory laparotomy for suspected gastrinoma; their surgeon insists that no anticoagulation be given. How would you treat? Dr. Rao presents such a complicated case to Dr. Montalescot.

Acute Coronary Syndromes

Meeting the Challenges in Long-Term Anticoagulation: Opportunities to Improve Patient Care

Aug 7, 2009 09:10 EDT

Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.

Thrombosis

Advancing Anticoagulation in Cardiovascular Medicine: Perspectives on Future Oral Therapies

Jul 31, 2009 11:00 EDT

The treatment options for oral anticoagulation therapy are constantly evolving. Join our expert panel, Drs. Graham Turpie, Jessica L. Mega, Jeffrey Weitz, as they discuss the new data and clinical implications of new anticoagulant medications for patients with ACS

Acute Coronary Syndromes

Antiplatelet Therapy: A Brazilian Expert's Take

1 COMMENT - Jul 14, 2009 12:00 EDT

From SOLACI 2009 in Rio de Janeiro. Dr. Mahmud hears how Dr. Feres interprets the data on antiplatelet/antithrombin strategies for his practice in Brazil.